Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements
Tarsus Pharmaceuticals (NASDAQ: TARS) reported record Q2 2025 financial results, achieving $102.7 million in net product sales for XDEMVY庐, a 152% increase year-over-year. The company distributed approximately 91,000 bottles to patients during the quarter, with over 90% coverage across commercial, Medicare, and Medicaid lives.
The company's Direct-To-Consumer campaign has significantly boosted performance, with consumer awareness of XDEMVY more than tripling and website engagement up 400% since early 2025. More than 20,000 Eye Care Professionals are now prescribing XDEMVY, exceeding the company's target of 15,000.
Despite strong sales growth, Tarsus reported a net loss of $20.3 million ($0.48 per share) for Q2 2025, improved from a $33.3 million loss in Q2 2024. The company maintains a strong cash position of $381.1 million as of June 30, 2025.
Tarsus Pharmaceuticals (NASDAQ: TARS) ha comunicato risultati finanziari record per il secondo trimestre del 2025, raggiungendo 102,7 milioni di dollari in vendite nette di prodotto per XDEMVY庐, con un incremento del 152% rispetto all'anno precedente. Durante il trimestre, l'azienda ha distribuito circa 91.000 flaconi ai pazienti, coprendo oltre il 90% delle vite commerciali, Medicare e Medicaid.
La campagna Direct-To-Consumer dell'azienda ha notevolmente migliorato le performance, con la consapevolezza del consumatore su XDEMVY pi霉 che triplicata e l'interazione sul sito web aumentata del 400% dall'inizio del 2025. Pi霉 di 20.000 professionisti della cura degli occhi prescrivono ora XDEMVY, superando l'obiettivo aziendale di 15.000.
Nonostante la forte crescita delle vendite, Tarsus ha registrato una perdita netta di 20,3 milioni di dollari (0,48 dollari per azione) nel secondo trimestre 2025, migliorata rispetto alla perdita di 33,3 milioni nel secondo trimestre 2024. L'azienda mantiene una solida posizione di cassa pari a 381,1 milioni di dollari al 30 giugno 2025.
Tarsus Pharmaceuticals (NASDAQ: TARS) report贸 resultados financieros r茅cord para el segundo trimestre de 2025, alcanzando 102,7 millones de d贸lares en ventas netas de productos para XDEMVY庐, un aumento del 152% interanual. La compa帽铆a distribuy贸 aproximadamente 91,000 frascos a los pacientes durante el trimestre, con una cobertura superior al 90% en vidas comerciales, Medicare y Medicaid.
La campa帽a Direct-To-Consumer de la empresa ha impulsado significativamente el desempe帽o, con el conocimiento del consumidor sobre XDEMVY m谩s que triplic谩ndose y la interacci贸n en el sitio web aumentando un 400% desde principios de 2025. M谩s de 20,000 profesionales del cuidado ocular est谩n ahora prescribiendo XDEMVY, superando la meta de la empresa de 15,000.
A pesar del fuerte crecimiento en ventas, Tarsus report贸 una p茅rdida neta de 20,3 millones de d贸lares (0,48 d贸lares por acci贸n) en el segundo trimestre de 2025, mejorando desde una p茅rdida de 33,3 millones en el segundo trimestre de 2024. La compa帽铆a mantiene una s贸lida posici贸n de efectivo de 381,1 millones de d贸lares al 30 de junio de 2025.
Tarsus Pharmaceuticals (NASDAQ: TARS)電� 2025雲� 2攵勱赴 鞁れ爜鞐愳劀 旮半鞝侅澑 靹标臣毳� 氤搓碃頃橂┌ XDEMVY庐鞚� 靾滌牅頀� 毵れ稖 1鞏� 270毵� 雼煬毳� 雼劚, 鞝勲厔 雽�牍� 152% 歃濌皜毳� 旮半頄堨姷雼堧嫟. 攵勱赴 霃欖晥 鞎� 91,000氤�鞚� 頇橃瀽鞐愱矊 鞙犿喌霅橃棃鞙茧┌, 靸侅梾, 氅旊敂旒�鞏�, 氅旊敂旒�鞚措摐 靾橅槣鞛� 欷� 90% 鞚挫儊鞚� 旎る矂頄堨姷雼堧嫟.
須岇偓鞚� Direct-To-Consumer 旌犿帢鞚胳潃 靹标臣毳� 韥矊 雭岇柎鞓牳鞙茧┌, XDEMVY鞐� 雽�頃� 靻岆箘鞛� 鞚胳霃勲姅 2025雲� 齑� 鞚错泟 3氚� 鞚挫儊 歃濌皜頄堦碃 鞗轨偓鞚错姼 彀胳棳霃勲姅 400% 靸侅姽頄堨姷雼堧嫟. 順勳灛 20,000氇� 鞚挫儊鞚� 鞎堦臣 鞝勲鞚�臧� XDEMVY毳� 觳橂癌頃橁碃 鞛堨柎 須岇偓 氇╉憸鞚� 15,000氇呾潉 齑堦臣頄堨姷雼堧嫟.
臧曤牓頃� 毵れ稖 靹膘灔鞐愲弰 攵堦惮頃橁碃 Tarsus電� 2025雲� 2攵勱赴鞐� 2,030毵� 雼煬 靾滌啇鞁�(欤茧嫻 0.48雼煬)鞚� 氤搓碃頄堨溂氅�, 鞚措姅 2024雲� 2攵勱赴 3,330毵� 雼煬 靻愳嫟鞐愳劀 臧滌劆霅� 靾橃箻鞛呺媹雼�. 須岇偓電� 2025雲� 6鞗� 30鞚� 旮办 3鞏� 8,110毵� 雼煬鞚� 臧曤牓頃� 順勱笀 氤挫湢瓿犽ゼ 鞙犾頃橁碃 鞛堨姷雼堧嫟.
Tarsus Pharmaceuticals (NASDAQ : TARS) a annonc茅 des r茅sultats financiers records pour le deuxi猫me trimestre 2025, atteignant 102,7 millions de dollars de ventes nettes de produits pour XDEMVY庐, soit une augmentation de 152 % par rapport 脿 l'ann茅e pr茅c茅dente. La soci茅t茅 a distribu茅 environ 91 000 flacons aux patients au cours du trimestre, avec une couverture de plus de 90 % des b茅n茅ficiaires commerciaux, Medicare et Medicaid.
La campagne Direct-To-Consumer de l'entreprise a consid茅rablement am茅lior茅 les performances, la notori茅t茅 des consommateurs pour XDEMVY ayant plus que tripl茅 et l'engagement sur le site web ayant augment茅 de 400 % depuis d茅but 2025. Plus de 20 000 professionnels des soins oculaires prescrivent d茅sormais XDEMVY, d茅passant l'objectif de l'entreprise de 15 000.
Malgr茅 une forte croissance des ventes, Tarsus a enregistr茅 une perte nette de 20,3 millions de dollars (0,48 dollar par action) pour le deuxi猫me trimestre 2025, une am茅lioration par rapport 脿 la perte de 33,3 millions au deuxi猫me trimestre 2024. La soci茅t茅 maintient une solide position de tr茅sorerie de 381,1 millions de dollars au 30 juin 2025.
Tarsus Pharmaceuticals (NASDAQ: TARS) meldete Rekordergebnisse f眉r das zweite Quartal 2025 und erzielte 102,7 Millionen US-Dollar Nettoproduktumsatz f眉r XDEMVY庐, was einem Anstieg von 152 % gegen眉ber dem Vorjahr entspricht. Das Unternehmen verteilte im Quartal etwa 91.000 Flaschen an Patienten und erreichte dabei eine Abdeckung von 眉ber 90 % bei kommerziellen, Medicare- und Medicaid-Versicherten.
Die Direct-To-Consumer-Kampagne des Unternehmens hat die Leistung deutlich gesteigert, wobei das Verbraucherbewusstsein f眉r XDEMVY sich mehr als verdreifacht hat und die Website-Interaktion seit Anfang 2025 um 400 % gestiegen ist. Mehr als 20.000 Augenpflegefachkr盲fte verschreiben nun XDEMVY und 眉bertreffen damit das Unternehmensziel von 15.000.
Trotz starkem Umsatzwachstum meldete Tarsus einen Nettoverlust von 20,3 Millionen US-Dollar (0,48 US-Dollar pro Aktie) f眉r das zweite Quartal 2025, eine Verbesserung gegen眉ber dem Verlust von 33,3 Millionen US-Dollar im zweiten Quartal 2024. Das Unternehmen verf眉gt zum 30. Juni 2025 眉ber eine starke Liquidit盲tsposition von 381,1 Millionen US-Dollar.
- Record quarterly net product sales of $102.7M, up 152% year-over-year
- Strong market penetration with 91,000 bottles distributed in Q2, up from 37,000 in prior year
- Over 90% coverage across commercial, Medicare and Medicaid lives
- Consumer website engagement up 400% since early 2025
- Prescriber base expanded to 20,000 ECPs, exceeding 15,000 target
- Net loss improved to $20.3M from $33.3M year-over-year
- Robust cash position of $381.1M as of Q2 2025
- Significant increase in SG&A expenses to $103.0M from $58.8M year-over-year
- High gross-to-net discount of approximately 45%
- Continued net losses despite revenue growth
- R&D expenses increased to $15.6M from $12.3M year-over-year
Insights
Tarsus reports record Q2 sales of $102.7M for XDEMVY, up 152% YoY, despite ongoing net losses amid aggressive marketing investments.
Tarsus Pharmaceuticals has delivered exceptional commercial execution with XDEMVY, reaching
The company's direct-to-consumer campaign has clearly gained traction, with website engagement up nearly
Despite these impressive topline results, Tarsus continues to operate at a loss, reporting a quarterly net loss of
The
The improving loss profile alongside robust revenue growth suggests Tarsus is approaching an inflection point toward profitability, assuming they can begin to moderate marketing expenses while maintaining sales momentum. Management's comments about XDEMVY's peak potential being higher than initially expected signal confidence in the product's long-term trajectory and market adoption.
Record quarterly net product sales of
Direct-To-Consumer campaign has activated new patients, expanded base and depth of prescribers and led to a meaningful increase in prescriptions
Pipeline advancements and global efforts remain on track
Management to host conference call today, August听6, 2025, at 1:30 p.m. PT / 4:30 p.m. ET
IRVINE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced financial results for the second quarter ended June听30, 2025.
鈥淎s we approach the two-year anniversary of the XDEMVY launch, we have delivered our strongest quarter to date with over
Recent Business and Clinical Highlights
- XDEMVY is one of the fastest growing and best-selling launches in the prescription eye drop segment with Q2 results of:
$102.7 million in net product sales.- Approximately 91,000 bottles distributed to patients.
- More than
90% of commercial, Medicare and Medicaid lives covered. - Approximately
45% gross-to-net discount.
- The Company鈥檚 action-oriented direct-to-consumer (DTC) advertising campaign meaningfully contributed to prescription growth, resulting from new patients and subsequent increase in Eye Care Professionals (ECPs) diagnosing Demodex blepharitis and writing prescriptions.
- Active consumer engagement on our XDEMVY.com website is up nearly
400% since the beginning of 2025. - Consumer unaided awareness of XDEMVY has more than tripled since the beginning of the DTC campaign.
- More than 20,000 ECPs are now prescribing XDEMVY, a more than
30% increase since the beginning of 2025 and beyond the Company鈥檚 target list of approximately 15,000 ECPs.
- Active consumer engagement on our XDEMVY.com website is up nearly
- Clinical Development: the Company鈥檚 robust pipeline remains on track with plans to initiate:
- A Phase 2 study of TP-04 (lotilaner ophthalmic gel) for the potential treatment of ocular rosacea, a highly prevalent and underserved eye disease with no FDA-approved therapy, in H2 2025.
- A Phase 2 study of TP-05 (lotilaner oral tablet) for the potential prevention of Lyme disease in 2026.
- Global Expansion: Meetings with regulatory authorities in Japan remain on track for H2 2025 and potential European regulatory approval for a preservative-free formulation of XDEMVY is expected in 2027.
Second Quarter 2025 Financial Results
- Product sales, net: were
$102.7 million compared to$40.8 million for the same period in 2024, driven by approximately 91,000 bottles of XDEMVY delivered to patients compared to approximately 37,000 bottles delivered in the prior year period. - Cost of sales: were
$6.2 million compared to$3.0 million for the same period in 2024, due to manufacturing costs related to XDEMVY, the royalty we pay on net product sales, and the amortization of the milestones paid to our licensor, which is being amortized over its remaining useful life. - Research and development (R&D) expenses: were
$15.6 million compared to$12.3 million for the same period in 2024. The increase was primarily due to$0.8 million of increased TP-04 program expenses,$1.3 million of increased payroll and personnel-related costs,$1.0 million of increased early-stage programs, and$0.3 million of increased other indirect expenses. These increases were partially offset by$0.2 million of decreased TP-03 program expenses. Total R&D non-cash stock compensation expense was$1.9 million , which was consistent with$1.9 million in the same period in 2024. - Selling, general and administrative (SG&A) expenses: were
$103.0 million compared to$58.8 million for the same period in 2024. The increase was due primarily to$7.1 million of increased payroll and personnel-related costs (including non-cash stock-based compensation),$30.2 million of increased commercial and marketing costs, including direct-to-consumer advertising costs, as we continued our commercial launch of XDEMVY, and$6.9 million of increased information technology applications, legal, professional, and other corporate expenses. Total SG&A non-cash stock compensation expense was$6.1 million , compared with$5.4 million in the same period in 2024. - Net loss: was
$20.3 million , compared to$33.3 million for the same period in 2024. Basic and diluted net loss per share for the quarter ended June听30, 2025 was$(0.48) , compared with$(0.88) for the same period in 2024. - Cash position: As of June听30, 2025, cash, cash equivalents and marketable securities were
$381.1 million .
Year-to-Date 2025 Financial Results
- Product sales: were
$181.0 million compared to$65.5 million for the same period in 2024, driven by approximately 163,000 bottles of XDEMVY delivered to patients compared to approximately 63,000 bottles delivered in the prior year period.
- Cost of sales: were
$11.4 million compared to$4.7 million for the same period in 2024, due to manufacturing costs related to XDEMVY, the royalty we pay on net product sales, and the amortization of the milestones paid to our licensor, which is being amortized over its remaining useful life.
- Research and development (R&D) expenses: were
$30.0 million compared to$24.4 million for the same period in 2024. The increase was due to$2.2 million of increased compensation and other employee-related expense (including non-cash stock-based compensation),$0.6 million of other indirect expenses,$1.9 million of increased early-stage programs,$1.3 million of increased TP-04 program spend, and$0.2 million more program spend for TP-05, partially offset by$0.7 million of decreased TP-03 program spend. R&D non-cash stock compensation expense was$3.4 million , compared with$3.3 million in the same period in 2024.
- Selling, general and administrative (SG&A) expenses: were
$188.0 million compared to$110.4 million for the same period in 2024. The increase was due primarily to$16.6 million of increased payroll and personnel-related costs (including non-cash stock-based compensation),$55.9 million of increased commercial and marketing costs, including direct-to-consumer advertising costs, related to the commercial launch of XDEMVY, and$5.0 million of increased IT, legal, professional and other corporate expenses. SG&A non-cash stock compensation expense was$11.4 million , compared with$9.3 million in the same period in 2024.
- Net loss: was
$45.5 million , compared to$69.0 million for the same period in 2024. Year-to-date basic and diluted net loss per share was$(1.11) , compared with$(1.89) for the same period in 2024.
Conference Call and Webcast
Tarsus will host a conference call and webcast to discuss its second quarter 2025 financial results and business highlights today, August听6, 2025, at 1:30 p.m. PT / 4:30 p.m. ET. A live webcast will be available on the events section of the Tarsus website. A recorded version of the call will be available on the website shortly after the completion of the call and will be archived there for at least 90 days.
About XDEMVY庐
XDEMVY (lotilaner ophthalmic solution)
XDEMVY Indication and Important Safety Information
INDICATIONS AND USAGE
XDEMVY is indicated for the treatment of Demodex blepharitis.
Most common side effects: The most common side effect in clinical trials was stinging and burning in
For additional information, please see full prescribing information available at: https://xdemvy.com/.
About TP-03
TP-03 (lotilaner ophthalmic solution)
About TP-04
TP-04 is an investigational sterile aqueous gel formulation of lotilaner. Tarsus is studying TP-04 for the potential treatment of ocular rosacea (OR).
About TP-05
TP-05 is an investigational oral systemic formulation of lotilaner. TP-05 is believed to be the only non-vaccine, drug-based, preventative therapeutic in development designed to kill ticks to potentially prevent Lyme disease transmission.
About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology, and infectious disease prevention. XDEMVY (lotilaner ophthalmic solution)
Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute 鈥渇orward-looking statements.鈥� These statements include statements regarding the potential commercial success and growth of XDEMVY in Demodex blepharitis, including market size, acceptance, demand, prescription fill rate and adoption rate for XDEMVY; our ability to successfully implement and continue our new direct-to-consumer campaign; our ability to achieve and maintain distribution and patient access for XDEMVY and timing and breadth of payer coverage; our ability to continue to educate the market about Demodex blepharitis; our ability to initiate planned clinical studies; anticipated regulatory and development milestones including potential Europe and Japan regulatory pathways and approval for XDEMVY; the results of our clinical studies; the test results of our pipeline formulations; our ability to continue investing in our business and actively evaluate external opportunities, and the quotations of Tarsus鈥� management. The words, without limitation, 鈥渂elieve,鈥� 鈥渃ontemplate,鈥� 鈥渃ontinue,鈥� 鈥渃ould,鈥� 鈥渆stimate,鈥� 鈥渆xpect,鈥� 鈥渋ntend,鈥� 鈥渕ay,鈥� 鈥渕ight,鈥� 鈥減lan,鈥� 鈥減otential,鈥� 鈥減redict,鈥� 鈥減roject,鈥� 鈥渟hould,鈥� 鈥渢arget,鈥� 鈥渨ill,鈥� or 鈥渨ould,鈥� or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Important factors that could cause actual results to differ materially from those in the forward-looking statements include: Tarsus is heavily dependent on the successful commercialization of its lead product, XDEMVY for the treatment of Demodex blepharitis and the development and regulatory approval and commercialization of its current and future product candidates; Tarsus鈥� ability to obtain and maintain regulatory approval for and successfully commercialize its products, including XDEMVY for the treatment of Demodex blepharitis, and its product candidates to meet existing and future regulatory standards; Tarsus has incurred significant losses and negative cash flows from operations since inception and anticipates that it will continue to incur significant expenses and losses for the foreseeable future; Tarsus鈥� capital requirements are difficult to predict and may change; Tarsus may need to obtain additional funding to achieve its goals and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force Tarsus to delay, reduce, or eliminate its product development programs, commercialization efforts or other operations; Tarsus may not be successful in educating healthcare professionals and the market about the need for treatments specifically for Demodex blepharitis and other diseases targeted by XDEMVY or our product candidates; the development and commercialization of Tarsus products is dependent on intellectual property it licenses from Elanco Tiergesundheit AG; Tarsus expects to expand its development, regulatory, operational, sales, and marketing capabilities and Tarsus may encounter difficulties in managing its growth, which could disrupt its operations; the sizes of the market opportunity for XDEMVY and Tarsus鈥� product candidates, particularly TP-04 for the potential treatment of ocular rosacea, as well as TP-05 for the potential prevention of Lyme disease, have not been established with precision and may be smaller than estimated; the results of Tarsus鈥� earlier studies and trials may not be predictive of future results; any termination or suspension of, or delays in the commencement or completion of, Tarsus鈥� planned clinical trials could result in increased costs, delay or limit its ability to generate revenue and adversely affect its commercial prospects; if Tarsus is unable to obtain and maintain sufficient intellectual property protection for its product candidates, or if the scope of the intellectual property protection is not sufficiently broad, Tarsus鈥� competitors could develop and commercialize products similar or identical to Tarsus鈥� products; and if Tarsus is unable to access capital (including but not limited to cash, cash equivalents, and credit facilities) and/or loses capital, as a result of potential failure of any financial institutions that Tarsus does business with directly or indirectly. Further, there are other risks and uncertainties that could cause actual results to differ from those set forth in the forward-looking statements and they are detailed from time to time in the reports Tarsus files with the Securities and Exchange Commission, including Tarsus鈥� Form 10-K for the year ended December 31, 2024 filed on February 25, 2025 and the most recent Form 10-Q quarterly filing filed with the SEC on August听6, 2025, which Tarsus incorporates by reference into this press release, copies of which are posted on its website and are available from Tarsus without charge. However, new risk factors and uncertainties may emerge from time to time, and it is not possible to predict all risk factors and uncertainties. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. Any forward-looking statements contained in this earnings release are based on the current expectations of Tarsus鈥� management team and speak only as of the date hereof, and Tarsus specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
| Media Contact: |
| Adrienne Kemp |
| Sr. Director, Corporate Communications |
| (949) 922-0801 |
| [email protected] |
| 听 |
| Investor Contact: |
| David Nakasone |
| Head of Investor Relations |
| (949) 620-3223 |
| [email protected] |
| TARSUS PHARMACEUTICALS, INC. | |||||||||||||||
| 听 | |||||||||||||||
| CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (In thousands, except share and per share amounts) (unaudited) | |||||||||||||||
| 听 | |||||||||||||||
| 听 | Three Months Ended June 30, | 听 | Six Months Ended June 30, | ||||||||||||
| 听 | 听 | 2025 | 听 | 听 | 听 | 2024 | 听 | 听 | 听 | 2025 | 听 | 听 | 听 | 2024 | 听 |
| Revenues: | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||||||
| Product sales, net | $ | 102,660 | 听 | 听 | $ | 40,813 | 听 | 听 | $ | 180,995 | 听 | 听 | $ | 65,533 | 听 |
| License fees and collaboration revenue | 听 | 鈥� | 听 | 听 | 听 | 鈥� | 听 | 听 | 听 | 鈥� | 听 | 听 | 听 | 2,894 | 听 |
| Total revenues | 听 | 102,660 | 听 | 听 | 听 | 40,813 | 听 | 听 | 听 | 180,995 | 听 | 听 | 听 | 68,427 | 听 |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||||||
| Operating expenses: | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||||||
| Cost of sales | 听 | 6,237 | 听 | 听 | 听 | 3,004 | 听 | 听 | 听 | 11,448 | 听 | 听 | 听 | 4,658 | 听 |
| Research and development | 听 | 15,594 | 听 | 听 | 听 | 12,319 | 听 | 听 | 听 | 30,003 | 听 | 听 | 听 | 24,385 | 听 |
| Selling, general and administrative | 听 | 103,013 | 听 | 听 | 听 | 58,792 | 听 | 听 | 听 | 188,008 | 听 | 听 | 听 | 110,370 | 听 |
| Total operating expenses | 听 | 124,844 | 听 | 听 | 听 | 74,115 | 听 | 听 | 听 | 229,459 | 听 | 听 | 听 | 139,413 | 听 |
| Loss from operations before other income (expense) | 听 | (22,184 | ) | 听 | 听 | (33,302 | ) | 听 | 听 | (48,464 | ) | 听 | 听 | (70,986 | ) |
| Other income (expense): | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||||||
| Interest income | 听 | 4,229 | 听 | 听 | 听 | 4,130 | 听 | 听 | 听 | 7,683 | 听 | 听 | 听 | 7,247 | 听 |
| Interest expense | 听 | (2,240 | ) | 听 | 听 | (2,109 | ) | 听 | 听 | (4,453 | ) | 听 | 听 | (3,092 | ) |
| Loss on debt extinguishment | 听 | 鈥� | 听 | 听 | 听 | (1,944 | ) | 听 | 听 | 鈥� | 听 | 听 | 听 | (1,944 | ) |
| Other income (expense), net | 听 | (145 | ) | 听 | 听 | (65 | ) | 听 | 听 | (226 | ) | 听 | 听 | (246 | ) |
| Total other income (expense), net | 听 | 1,844 | 听 | 听 | 听 | 12 | 听 | 听 | 听 | 3,004 | 听 | 听 | 听 | 1,965 | 听 |
| Net loss | $ | (20,340 | ) | 听 | $ | (33,290 | ) | 听 | $ | (45,460 | ) | 听 | $ | (69,021 | ) |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||||||
| Unrealized gain (loss) on marketable securities and cash equivalents | 听 | (46 | ) | 听 | 听 | (113 | ) | 听 | 听 | (140 | ) | 听 | 听 | (174 | ) |
| Comprehensive loss | $ | (20,386 | ) | 听 | $ | (33,403 | ) | 听 | $ | (45,600 | ) | 听 | $ | (69,195 | ) |
| 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||||||
| Net loss per share, basic and diluted | $ | (0.48 | ) | 听 | $ | (0.88 | ) | 听 | $ | (1.11 | ) | 听 | $ | (1.89 | ) |
| Weighted-average shares outstanding, basic and diluted | 听 | 42,360,452 | 听 | 听 | 听 | 37,823,233 | 听 | 听 | 听 | 40,869,364 | 听 | 听 | 听 | 36,530,756 | 听 |
| TARSUS PHARMACEUTICALS, INC. | |||||||
| 听 | |||||||
| CONDENSED BALANCE SHEETS (In thousands, except share and par value amounts) | |||||||
| 听 | 听 | ||||||
| 听 | June 30, 2025 | 听 | December 31, 2024 | ||||
| 听 | (unaudited) | 听 | 听 | ||||
| ASSETS | 听 | 听 | 听 | ||||
| Current assets: | 听 | 听 | 听 | ||||
| Cash and cash equivalents | $ | 96,648 | 听 | 听 | $ | 94,819 | 听 |
| Marketable securities | 听 | 284,495 | 听 | 听 | 听 | 196,557 | 听 |
| Accounts receivable, net | 听 | 58,334 | 听 | 听 | 听 | 46,760 | 听 |
| Inventory | 听 | 3,873 | 听 | 听 | 听 | 2,620 | 听 |
| Other receivables | 听 | 1,906 | 听 | 听 | 听 | 1,299 | 听 |
| Prepaid expenses | 听 | 29,173 | 听 | 听 | 听 | 14,650 | 听 |
| Total current assets | 听 | 474,429 | 听 | 听 | 听 | 356,705 | 听 |
| Restricted cash, non-current | 听 | 2,563 | 听 | 听 | 听 | 2,562 | 听 |
| Inventory, non-current | 听 | 2,532 | 听 | 听 | 听 | 2,533 | 听 |
| Property and equipment, net | 听 | 3,182 | 听 | 听 | 听 | 2,314 | 听 |
| Intangible assets, net | 听 | 7,846 | 听 | 听 | 听 | 8,326 | 听 |
| Operating lease right-of-use assets | 听 | 229 | 听 | 听 | 听 | 552 | 听 |
| Long-term investments | 听 | 3,000 | 听 | 听 | 听 | 3,000 | 听 |
| Other assets | 听 | 1,213 | 听 | 听 | 听 | 999 | 听 |
| Total assets | $ | 494,994 | 听 | 听 | $ | 376,991 | 听 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | 听 | 听 | 听 | ||||
| Current liabilities: | 听 | 听 | 听 | ||||
| Accounts payable and other accrued liabilities | $ | 78,641 | 听 | 听 | $ | 64,789 | 听 |
| Accrued payroll and benefits | 听 | 11,612 | 听 | 听 | 听 | 15,823 | 听 |
| Total current liabilities | 听 | 90,253 | 听 | 听 | 听 | 80,612 | 听 |
| Long-term debt, net | 听 | 72,129 | 听 | 听 | 听 | 71,845 | 听 |
| Total liabilities | 听 | 162,382 | 听 | 听 | 听 | 152,457 | 听 |
| Commitments and contingencies | 听 | 听 | 听 | ||||
| Stockholders鈥� equity: | 听 | 听 | 听 | ||||
| Preferred stock, | 听 | 鈥� | 听 | 听 | 听 | 鈥� | 听 |
| Common stock, | 听 | 6 | 听 | 听 | 听 | 6 | 听 |
| Additional paid-in capital | 听 | 738,237 | 听 | 听 | 听 | 584,559 | 听 |
| Accumulated other comprehensive income (loss) | 听 | 39 | 听 | 听 | 听 | 179 | 听 |
| Accumulated deficit | 听 | (405,670 | ) | 听 | 听 | (360,210 | ) |
| Total stockholders鈥� equity | 听 | 332,612 | 听 | 听 | 听 | 224,534 | 听 |
| Total liabilities and stockholders鈥� equity | $ | 494,994 | 听 | 听 | $ | 376,991 | 听 |
FAQ
What were Tarsus Pharmaceuticals (TARS) Q2 2025 earnings results?
How many healthcare professionals are prescribing XDEMVY in 2025?
What is the insurance coverage for Tarsus' XDEMVY medication?
What is Tarsus' (TARS) cash position as of Q2 2025?
What are Tarsus' upcoming pipeline developments?
